Qube Holdings – Review

Posted on | by Leon Hinde

Qube Holdings is now under Algo Engine buy conditions and as part of the review, we take a closer look at the FY20 earnings results.

COVID has had a negative impact on overall volumes and we expect to see a gradual improvement over FY21 and FY22.

About

Qube is Australia’s largest integrated provider of import and export logistics services with a market capitalisation in excess of $4.88 billion as at 30 June 2019.

We operate in over 130 locations across Australia, New Zealand and South East Asia with a workforce of over 6,500 employees.

Qube is comprised of three business units including Ports, Bulk and Logistics division, Infrastructure and Property division and Strategic Assets division. We also hold a 50 percent interest in Patrick Terminals, Australia’s leading container terminal operator.

FY20 Earnings

Pro Medicus – Contract Win

Posted on | by Leon Hinde

Pro Medicus is under Algo Engine buy conditions.

PME announced a $25m seven year deal with NYU Langone Healthcare, which has now followed the recent $22m 5 year deal with Northwestern Memorial Healthcare.

These deals provide further evidence of Pro Medicus’ acceptance among some of the largest hospital groups in the US.

The stock is expensive, but the growth story continues to look compelling.

Technically, we have seen a recent higher low with strong buying off the $24.50 level in Friday’s session.

MVP – Review

Posted on | by Leon Hinde

Medical Developments International is a stock that has been brought to my attention by a client, which has then prompted a review of the company.

About – Medical Developments International is one of Australia’s leading specialised healthcare companies. With an industry-leading range of products in the areas of pain management, asthma and resuscitation, plus veterinary equipment.

We’ll continue to monitor the MVP business and we’ll conduct further research on the potential drivers of future revenue and profit growth.

In the meantime, Pro Medicus remains our prefered “high growth” medical play, but we now add MVP to our watchlist.